Patients with depression that could benefit from a tricyclic antidepressant (TCA) as first-line therapy*

- Patients who have been diagnosed with severe depression
- Patients showing psychomotor retardation or lack of energy
- Patients presenting symptoms or with a pre-existing history of insomnia
- Patients presenting symptoms or with a pre-existing history of irritable bowel syndrome
- Patients with anxiety or agitation due to depression
- Patients with weight loss due to depression
- Patients with potential cytochrome P450 drug-drug interactions
- Patients with a history of hyponatremia

Important Safety Information: Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of imipramine pamoate or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Tofranil-PM™ is not approved for use in pediatric patients.

For more information about Tofranil-PM™, please see the attached full Prescribing Information.

Tofranil-PM™ is an effective TCA for the physical and emotional symptoms of depression

- Significantly reduces depressive symptoms in 1 to 2 weeks\(^6\)
- Provides the strongest effects on norepinephrine and serotonin reuptake among all TCAs\(^7\)
- Proven well tolerated in head-to-head studies\(^8\)-\(^10\)
- Is available in a convenient, once-daily capsule
- Is available in a generic, imipramine pamoate

When a TCA is the appropriate choice

**Tofranil-PM™**
imipramine pamoate

**Powerful therapy for serious symptoms**

| 75 mg | 100 mg | 125 mg | 150 mg |

For more information about Tofranil-PM™, please see the attached full Prescribing Information.

See references beneath the Prescribing Information.

References:

COVIDIEN, COVIDIEN with Logo, and ™ marked brands are trademarks of Covidien AG or an affiliate.